CervoMed Inc. (CRVO)
Nasdaq · Healthcare · Biotechnology
$3.31+9.60%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $50.0M
- 52-week range
- $2.13 – $10.00
- 52-week change
- −64.97%
- EPS (trailing)
- −$3.21
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $4.0M (−58.86%)
- Net income
- −$27.0M
- Operating margin
- −706.2%
From the company’s annual report on SEC EDGAR.
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Headquarters: Boston, United States · 15 employees · cervomed.com